Leonela Amoasii

Leonela Amoasii

Auto-generated profile, based on publicly available information

Leonela Amoasii

Department of Molecular Biology, Hamon Center for Regenerative Science and Medicine, Sen. Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2018 in Science
Verified
Journal Article
Closed access
PDF file
LALeonela Amoasii
Leonela Amoasii
JHJohn C.W. Hildyard
John C.W. Hildyard
HLHui Li
Hui Li
ESEfrain Sanchez-Ortiz
Efrain Sanchez-Ortiz
AMAlex Mireault
Alex Mireault
EOEric N. Olson
Eric N. Olson
Gene editing and muscular dystrophy: Duchenne muscular dystrophy (DMD) is characterized by progressive muscle weakness and a shortened life span. The disease is caused by mutations that reduce or prevent expression of dystrophin, an essential structural protein in skeletal and heart muscle. The gene editing technology CRISPR-Cas9 can correct disease-causing mutations and has yielded promising results in mouse models of DMD. In a small, short-term study, Amoasii et al. tested this strategy in a dog model of DMD that exhibits many features of the human disease. Intramuscular or systemic delivery of the gene editing components resulted in a substantial increase in dystrophin protein levels in skeletal and heart muscle. Restoration of dystrophin expression was accompanied by improved muscle histology. Science , this issue p. 86

29 November 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
LALeonela Amoasii
Leonela Amoasii
CLChengzu Long
Chengzu Long
HLHui Li
Hui Li
AMAlex A. Mireault
Alex A. Mireault
JSJohn M. Shelton
John M. Shelton
EOEric N. Olson
Eric N. Olson
Single-cut correction of a dystrophin gene mutation with CRISPR/Cas9 restored dystrophin expression in skeletal and cardiac muscles in a mouse model of Duchenne muscular dystrophy.

4 January 2011 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KHKarim Hnia
Karim Hnia
HTHelene Tronchère
Helene Tronchère
KTKinga K. Tomczak
Kinga K. Tomczak
LALeonela Amoasii
Leonela Amoasii
PSPatrick Schultz
Patrick Schultz
JLJocelyn Laporte
Jocelyn Laporte
Muscle contraction relies on a highly organized intracellular network of membrane organelles and cytoskeleton proteins. Among the latter are the intermediate filaments (IFs), a large family of proteins mutated in more than 30 human diseases. For example, mutations in the DES gene, which encodes the IF desmin, lead to desmin-related myopathy and cardiomyopathy. Here, we demonstrate that myotubularin (MTM1), which is mutated in individuals with X-linked centronuclear myopathy (XLCNM; also known as myotubular myopathy), is a desmin-binding protein and provide evidence for direct regulation of desmin by MTM1 in vitro and in vivo. XLCNM-causing mutations in MTM1 disrupted the MTM1-desmin complex, resulting in abnormal IF assembly and architecture in muscle cells and both mouse and human skeletal muscles. Adeno-associated virus–mediated ectopic expression of WT MTM1 in Mtm1-KO muscle reestablished normal desmin expression and localization. In addition, decreased MTM1 expression and XLCNM-causing mutations induced abnormal mitochondrial positioning, shape, dynamics, and function. We therefore conclude that MTM1 is a major regulator of both the desmin cytoskeleton and mitochondria homeostasis, specifically in skeletal muscle. Defects in IF stabilization and mitochondrial dynamics appear as common physiopathological features of centronuclear myopathies and desmin-related myopathies.

1 May 2011 in The American Journal of Pathology
Verified
Journal Article
Closed access
BCBelinda S. Cowling
Belinda S. Cowling
ATAnne Toussaint
Anne Toussaint
LALeonela Amoasii
Leonela Amoasii
PKPascale Koebel
Pascale Koebel
AFArnaud Ferry
Arnaud Ferry
JLJocelyn Laporte
Jocelyn Laporte

21 May 2013 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
LALama Al‐Qusairi
Lama Al‐Qusairi
IPIvana Prokic
Ivana Prokic
LALeonela Amoasii
Leonela Amoasii
CKChristine Kretz
Christine Kretz
NMNadia Messaddeq
Nadia Messaddeq
JLJocelyn Laporte
Jocelyn Laporte
Mutations in the phosphoinositide phosphatase myotubularin (MTM1) results in X‐linked myotubular/centronuclear myopathy (XLMTM), characterized by a severe decrease in muscle mass and strength in patients and murine models. However, the molecular mechanism involved in the muscle hypotrophy is unclear. Here we show that the IGF1R/Akt pathway is affected in Mtm1 ‐deficient murine muscles, characterized by an increase in IGF1 receptor and Akt levels in both the presymptomatic and symptomatic phases. Moreover, up‐regulation of atrogenes was observed in the presymptomatic phase of the myopathy, supporting overactivation of the ubiquitin‐proteasome pathway. In parallel, the autophagy machinery was affected as indicated by the increase in the number of autophagosomes and of autophagy markers, such as LC3 and P62. However, phosphorylation of FOXO3a and mTOR were abnormal at late but not at early stages of the disease, suggesting that myotubularin acts both upstream in the IGF1R/Akt pathway and downstream on the balance between the autophagy and ubiquitin‐proteasome pathways in vivo . Adeno‐associated virus‐mediated delivery of Mtm1 into Mtm1 ‐null muscles rescued muscle mass and normalized the expression levels of IGF1 receptor, the ubiquitin‐proteasome pathway, and autophagy markers. These data support the hypothesis that the unbalanced regulation of the ubiquitin proteasome pathway and the autophagy machinery is a primary cause of the XLMTM pathogenesis.—Al‐Qusairi, L., Prokic, I., Amoasii, L., Kretz, C., Messaddeq, N., Mandel, J.‐L., Laporte, J. Lack of myotubularin (MTM1) leads to muscle hypotrophy through unbalanced regulation of the autophagy and ubiquitin‐proteasome pathways. FASEB J. 27, 3384–3394 (2013). www.fasebj.org

14 March 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
VDVincent Duheron
Vincent Duheron
EHEstelle Hess
Estelle Hess
MDMonique Duval
Monique Duval
MDMarion Decossas
Marion Decossas
BCBeatriz Castaneda
Beatriz Castaneda
CMChristopher G. Mueller
Christopher G. Mueller
Receptor activator of NF-κB (RANK), known for controlling bone mass, has been recognized for its role in epithelial cell activation of the mammary gland. Because bone and the epidermo-pilosebaceous unit of the skin share a lifelong renewal activity where similar molecular players operate, and because mammary glands and hair follicles are both skin appendages, we have addressed the function of RANK in the hair follicle and the epidermis. Here, we show that mice deficient in RANK ligand (RANKL) are unable to initiate a new growth phase of the hair cycle and display arrested epidermal homeostasis. However, transgenic mice overexpressing RANK in the hair follicle or administration of recombinant RANKL both activate the hair cycle and epidermal growth. RANK is expressed by the hair follicle germ and bulge stem cells and the epidermal basal cells, cell types implicated in the renewal of the epidermo-pilosebaceous unit. RANK signaling is dispensable for the formation of the stem cell compartment and the inductive hair follicle mesenchyme, and the hair cycle can be rescued by Rankl knockout skin transplantation onto nude mice. RANKL is actively transcribed by the hair follicle at initiation of its growth phase, providing a mechanism for stem cell RANK engagement and hair-cycle entry. Thus, RANK–RANKL regulates hair renewal and epidermal homeostasis and provides a link between these two activities.